Nordic Nanovector spikes after gaining go to start pivotal study

Top 50 shareholders list has only shown fairly minor changes during recent share price turmoil, but huge retail following were delighted to see Nordic Nanovector finally land approval to go ahead with PARADIGME pivotal clinical study. NANO spikes back 23.99%.

One interesting factor is the substantial gap between 63 and 68 NOK, with more positive news coming the share price may be set to go back to the 68-84 trading range from 2017.